MCID: OVR044
MIFTS: 31

Ovarian Carcinosarcoma malady

Categories: Rare diseases, Reproductive diseases, Cancer diseases

Aliases & Classifications for Ovarian Carcinosarcoma

Aliases & Descriptions for Ovarian Carcinosarcoma:

Name: Ovarian Carcinosarcoma 12 50 56 14
Ovarian Malignant Mixed Epithelial Mesenchymal Tumor 56
Malignant Mixed Mullerian Tumor of the Ovary 50
Malignant Mixed Müllerian Tumor of the Ovary 56
Ovarian Malignant Mesodermal Mixed Tumor 12
Ovarian Malignant Mixed Mullerian Tumor 12
Ovarian Malignant Mixed Müllerian Tumor 56
Carcinosarcoma of Ovary 69
Mmmt of the Ovary 56
Ovarian Mmmt 12

Characteristics:

Orphanet epidemiological data:

56

Classifications:



External Ids:

Disease Ontology 12 DOID:6170
NCIt 47 C9192
SNOMED-CT 64 702368000
Orphanet 56 ORPHA213512
ICD10 via Orphanet 34 C56
UMLS 69 C0392998

Summaries for Ovarian Carcinosarcoma

NIH Rare Diseases : 50 ovarian carcinosarcoma is a cancer of the ovary that is composed of two types of cells, namely carcinoma cells and sarcoma cells.  ovarian carcinosarcoma is also known as a malignant mixed mullerian tumor of the ovary.  the average age of women at the time of diagnosis is 60 to 70 years.  symptoms may include pain in the abdomen or pelvic area, bloating or swelling of the abdomen, quickly feeling full when eating or other digestive issues.  the cause of ovarian carcinosarcoma is currently unknown.  treatment usually consists of surgery (sometimes called debulking) and chemotherapy. last updated: 9/4/2012

MalaCards based summary : Ovarian Carcinosarcoma, also known as ovarian malignant mixed epithelial mesenchymal tumor, is related to malignant mixed mullerian tumor and diffuse cutaneous mastocytosis. An important gene associated with Ovarian Carcinosarcoma is TUBB3 (Tubulin Beta 3 Class III). The drugs Carboplatin and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include ovary and small intestine.

Related Diseases for Ovarian Carcinosarcoma

Graphical network of the top 20 diseases related to Ovarian Carcinosarcoma:



Diseases related to Ovarian Carcinosarcoma

Symptoms & Phenotypes for Ovarian Carcinosarcoma

Drugs & Therapeutics for Ovarian Carcinosarcoma

Drugs for Ovarian Carcinosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 87)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
2
Ifosfamide Approved Phase 3 3778-73-2 3690
3
Mechlorethamine Approved Phase 3 51-75-2 4033
4
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
5
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
6
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
7
Lenograstim Approved Phase 3,Phase 1 135968-09-1
8
Cyproheptadine Approved Phase 3 129-03-3 2913
9
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
10
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
11 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
12 Alkylating Agents Phase 3,Phase 2
13 Antimitotic Agents Phase 3,Phase 2,Phase 1
14 Antineoplastic Agents, Alkylating Phase 3,Phase 2
15 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
16 Isophosphamide mustard Phase 3
17 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
18 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
19 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
20 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
21 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
22 Anti-Allergic Agents Phase 3
23 Antipruritics Phase 3
24 Dermatologic Agents Phase 3
25 Gastrointestinal Agents Phase 3
26 Histamine Antagonists Phase 3
27 Histamine H1 Antagonists Phase 3
28
Histamine Phosphate Phase 3 51-74-1 65513
29 Neurotransmitter Agents Phase 3
30
Serotonin Phase 3 50-67-9 5202
31 Serotonin Agents Phase 3
32 Serotonin Antagonists Phase 3
33
Cisplatin Approved Phase 2,Phase 1 15663-27-1 84093 441203 2767
34
Gemcitabine Approved Phase 2 95058-81-4 60750
35
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
36
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
37
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
38
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
39
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
40
nivolumab Approved Phase 2 946414-94-4
41
Everolimus Approved Phase 2 159351-69-6 6442177
42
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
43
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
44
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
45
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
46
Nicotinamide Approved, Nutraceutical Phase 2 98-92-0 936
47 Anti-Infective Agents Phase 2
48 Antimetabolites Phase 2,Phase 1
49 Antimetabolites, Antineoplastic Phase 2,Phase 1
50 Antiviral Agents Phase 2

Interventional clinical trials:

(show all 37)
id Name Status NCT ID Phase
1 Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Unknown status NCT00954174 Phase 3
2 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3
3 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3
4 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
5 Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer Unknown status NCT00511992 Phase 2
6 Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Unknown status NCT00838656 Phase 2
7 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2
8 Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2
9 Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma Completed NCT00390234 Phase 2
10 Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract Completed NCT00003334 Phase 2
11 Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer Completed NCT00032162 Phase 1, Phase 2
12 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2
13 Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors Completed NCT00520013 Phase 2
14 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2
15 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2
16 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2
17 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2
18 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT02101775 Phase 2
19 Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Recruiting NCT01935934 Phase 2
20 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
21 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Active, not recruiting NCT01010126 Phase 2
22 Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Active, not recruiting NCT00478426 Phase 2
23 Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)_MITO 26 Not yet recruiting NCT02993705 Phase 2
24 A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers Not yet recruiting NCT02923934 Phase 2
25 A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma Unknown status NCT01454479 Phase 1
26 Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer Completed NCT00352300 Phase 1
27 Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) Completed NCT00085358 Phase 1
28 Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors Completed NCT00066651 Phase 1
29 Immunotoxin Therapy in Treating Patients With Advanced Cancer Completed NCT00006981 Phase 1
30 Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors Completed NCT00413322 Phase 1
31 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Recruiting NCT02020707 Phase 1
32 Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT00989651 Phase 1
33 Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial Completed NCT00904514
34 Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Active, not recruiting NCT01080521
35 Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Active, not recruiting NCT01440998
36 Endometrial Cancer and Fractalkine-receptor Axis of Fractalkine Not yet recruiting NCT02774395
37 Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient No longer available NCT02090127

Search NIH Clinical Center for Ovarian Carcinosarcoma

Genetic Tests for Ovarian Carcinosarcoma

Anatomical Context for Ovarian Carcinosarcoma

MalaCards organs/tissues related to Ovarian Carcinosarcoma:

39
Ovary, Small Intestine

Publications for Ovarian Carcinosarcoma

Articles related to Ovarian Carcinosarcoma:

(show all 39)
id Title Authors Year
1
Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study. ( 27958685 )
2017
2
Patterns of care, predictors and outcomes of chemotherapy for ovarian carcinosarcoma: A National Cancer Database analysis. ( 27107722 )
2016
3
Mature Teratoma Associated with Bilateral Ovarian Carcinosarcoma - Accidental Association or Etiopathogenetic Determinism? - Case Report. ( 27819640 )
2016
4
Ovarian Carcinosarcoma and Its Association with Mature Cystic Teratoma and Primary Tubal Carcinoma. ( 27807494 )
2016
5
Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft. ( 25962155 )
2015
6
Presence of both Mesenchymal and Carcinomatous Features in an In-vitro Model of Ovarian Carcinosarcoma Derived from Patients' Ascitic Fluid. ( 25802693 )
2015
7
Ovarian carcinosarcoma: a case report, diagnosis, treatment and literature review. ( 27418786 )
2015
8
Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTEAr), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro. ( 26474755 )
2015
9
Radical surgical cytoreduction in the treatment of ovarian carcinosarcoma. ( 24631447 )
2014
10
Rhabdomyosarcoma with pseudolipoblasts arising in ovarian carcinosarcoma: a distinctive postchemotherapy morphologic variant mimicking pleomorphic liposarcoma. ( 24587930 )
2014
11
Ovarian carcinosarcoma in a renal transplant recipient. A unique case of a rare tumor. ( 26052208 )
2014
12
A rare case of ovarian carcinosarcoma with neuroendocrine differentiation. ( 24971408 )
2014
13
Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine and Ovarian Carcinosarcoma. ( 25341582 )
2014
14
Large polyp of the small intestine: an unexpected metastasis of ovarian carcinosarcoma. ( 23926191 )
2013
15
Ovarian carcinosarcoma associated with bilateral tubal intraepithelial carcinoma: a case report. ( 23722511 )
2013
16
Ovarian carcinosarcoma: effects of cytoreductive status and platinum-based chemotherapy on survival. ( 23781249 )
2013
17
Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma. ( 23450567 )
2013
18
Prognostic determinants in patients with uterine and ovarian carcinosarcoma. ( 23947079 )
2013
19
Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression. ( 22209775 )
2012
20
Complete response with pegylated liposomal doxorubicin as a second-line therapy in metastatic ovarian carcinosarcoma: Significance of assessment of the response by FDG-PET. ( 24371621 )
2012
21
Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody. ( 22075385 )
2011
22
Malignant melanoma arising in an ovarian carcinosarcoma: case report and review of the literature. ( 21293284 )
2011
23
Whole-body FDG PET/CT in diagnosis of internal mammary nodal metastasis of ovarian carcinosarcoma. ( 21552025 )
2011
24
A rare case of ovarian carcinosarcoma successfully treated with the neoadjuvant chemotherapy of paclitaxel and ifosfamide. ( 21417665 )
2011
25
Solitary splenic metastasis from ovarian carcinosarcoma: a case report. ( 21310035 )
2011
26
Platinum, anthracycline, and alkylating agent-based chemotherapy for ovarian carcinosarcoma. ( 19820383 )
2009
27
Angiogenesis and expression of angiogenic agents in uterine and ovarian carcinosarcomas. ( 18321361 )
2008
28
Current management of ovarian carcinosarcoma. ( 17362309 )
2007
29
A case of primary ovarian carcinosarcoma and vulvar carcinoma with widespread lymphadenopathy. ( 16846899 )
2006
30
Complete cytoreduction combined with early postoperative intraperitoneal chemotherapy for ovarian carcinosarcoma. Report of two cases. ( 16645301 )
2006
31
Clinical features and outcomes of uterine and ovarian carcinosarcoma. ( 16271748 )
2006
32
Clinicopathological features of ovarian carcinosarcomas: a single institution experience. ( 15589592 )
2005
33
Primary ovarian carcinosarcoma: a case report and review of the literature. ( 15493190 )
2004
34
Transition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesis. ( 12893202 )
2003
35
Unusual Trousseau's syndrome in ovarian carcinosarcoma: multiple systemic thromboembolic events. ( 12554280 )
2002
36
Ovarian carcinosarcoma [correction of carcinoma]. ( 11418412 )
2001
37
Borderline serous cystadenocarcinoma with coexistent angiosarcoma: an unusual form of ovarian carcinosarcoma. ( 12574850 )
2001
38
Prognostic factors in ovarian carcinosarcoma: a clinicopathological and immunohistochemical analysis of 23 cases. ( 11119124 )
2000
39
MR images of ovarian carcinosarcoma. ( 10646984 )
1999

Variations for Ovarian Carcinosarcoma

Expression for Ovarian Carcinosarcoma

Search GEO for disease gene expression data for Ovarian Carcinosarcoma.

Pathways for Ovarian Carcinosarcoma

GO Terms for Ovarian Carcinosarcoma

Sources for Ovarian Carcinosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....